β-1, 3-galactosyltransferase 2 ameliorates focal ischemic cerebral injury by maintaining blood-brain barrier integrity
Copyright © 2021 Elsevier Ltd. All rights reserved..
Blood-brain barrier (BBB) damage at the early stage of ischemic stroke is a vital cause of brain parenchymal injury. The mechanism of BBB disruption has been intensively investigated, but still not fully understood. β-1, 3-galactosyltransferase 2 (B3galt2) is expressed in the brain, but its role in the pathogenesis of cerebral ischemia remains unknown. In this study, we investigated the role of B3galt2 in cerebral ischemia in mice. Focal cerebral ischemia was induced in mice by middle cerebral artery occlusion (MCAO). B3galt2 protein levels were determined in microvessels which were isolated from ischemic brain at 12, 24 and 72 h after MCAO. Mice were administered lentiviral vectors encoding B3galt2 (LV- B3galt2) or recombinant transforming growth factor-β1 (r-TGF-β1) by intracerebroventricular injection. We assessed infarct volume and neurologic deficits on days 1, 3, and 14 after MCAO, blood-brain barrier (BBB) integrity at 12 and 24 h after MCAO, and the levels of TGF-β1, TGF-βR(Ⅱ) and p-Smad2/3 at 24 and 72 h after MCAO. Our results indicated that B3galt2 was expressed in brain microvascular endothelial cells and increased in the ischemic microvessels. Overexpression of B3galt2 by LV- B3galt2 administration reduced infarct volume and improved functional outcome after cerebral ischemia. Moreover, the neuroprotective effects were associated with preventing BBB damage. Compared with wild-type (WT) mice, heterozygous B3galt2 knockout (B3galt2-/+) mice not only showed severe BBB damage, neurologic functional deficits, but also showed reduced expression of TGF-β1, TGF-βR(Ⅱ) and p-Smad2/3 in microvessels after cerebral ischemia. Pre-administration of r-TGF-β1 reduced BBB damage, and improved the neurological outcomes in both WT mice and B3galt2-/+ mice after cerebral ischemia. Our results suggested B3galt2 protected against ischemic stroke in mice, and the underlying mechanism might include TGF-β signaling pathway in brain microvascular endothelial cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:144 |
|---|---|
| Enthalten in: |
Neurochemistry international - 144(2021) vom: 01. März, Seite 104976 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Xue [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B3GALNT2 protein, human |
|---|
| Anmerkungen: |
Date Completed 12.11.2021 Date Revised 12.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.neuint.2021.104976 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320855813 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320855813 | ||
| 003 | DE-627 | ||
| 005 | 20231225174537.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neuint.2021.104976 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320855813 | ||
| 035 | |a (NLM)33524473 | ||
| 035 | |a (PII)S0197-0186(21)00022-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Xue |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a β-1, 3-galactosyltransferase 2 ameliorates focal ischemic cerebral injury by maintaining blood-brain barrier integrity |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.11.2021 | ||
| 500 | |a Date Revised 12.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Blood-brain barrier (BBB) damage at the early stage of ischemic stroke is a vital cause of brain parenchymal injury. The mechanism of BBB disruption has been intensively investigated, but still not fully understood. β-1, 3-galactosyltransferase 2 (B3galt2) is expressed in the brain, but its role in the pathogenesis of cerebral ischemia remains unknown. In this study, we investigated the role of B3galt2 in cerebral ischemia in mice. Focal cerebral ischemia was induced in mice by middle cerebral artery occlusion (MCAO). B3galt2 protein levels were determined in microvessels which were isolated from ischemic brain at 12, 24 and 72 h after MCAO. Mice were administered lentiviral vectors encoding B3galt2 (LV- B3galt2) or recombinant transforming growth factor-β1 (r-TGF-β1) by intracerebroventricular injection. We assessed infarct volume and neurologic deficits on days 1, 3, and 14 after MCAO, blood-brain barrier (BBB) integrity at 12 and 24 h after MCAO, and the levels of TGF-β1, TGF-βR(Ⅱ) and p-Smad2/3 at 24 and 72 h after MCAO. Our results indicated that B3galt2 was expressed in brain microvascular endothelial cells and increased in the ischemic microvessels. Overexpression of B3galt2 by LV- B3galt2 administration reduced infarct volume and improved functional outcome after cerebral ischemia. Moreover, the neuroprotective effects were associated with preventing BBB damage. Compared with wild-type (WT) mice, heterozygous B3galt2 knockout (B3galt2-/+) mice not only showed severe BBB damage, neurologic functional deficits, but also showed reduced expression of TGF-β1, TGF-βR(Ⅱ) and p-Smad2/3 in microvessels after cerebral ischemia. Pre-administration of r-TGF-β1 reduced BBB damage, and improved the neurological outcomes in both WT mice and B3galt2-/+ mice after cerebral ischemia. Our results suggested B3galt2 protected against ischemic stroke in mice, and the underlying mechanism might include TGF-β signaling pathway in brain microvascular endothelial cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a B3galt2 | |
| 650 | 4 | |a Blood-brain barrier | |
| 650 | 4 | |a Ischemia/reperfusion | |
| 650 | 4 | |a Stroke | |
| 650 | 4 | |a TGF-β | |
| 650 | 7 | |a B3GALNT2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.4.1.- |2 NLM | |
| 650 | 7 | |a N-Acetylgalactosaminyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.4.1.- |2 NLM | |
| 700 | 1 | |a Liang, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Mengjie |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Tianhui |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Xinyang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Pan |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Lili |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Zuo, Zhongfu |e verfasserin |4 aut | |
| 700 | 1 | |a Pei, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Bi, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Peng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurochemistry international |d 1980 |g 144(2021) vom: 01. März, Seite 104976 |w (DE-627)NLM012652016 |x 1872-9754 |7 nnns |
| 773 | 1 | 8 | |g volume:144 |g year:2021 |g day:01 |g month:03 |g pages:104976 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neuint.2021.104976 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 144 |j 2021 |b 01 |c 03 |h 104976 | ||